Related Experiment Video
Updated: Sep 18, 2025

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
Deciphering Radiotherapy Resistance: A Proteomic Perspective
Davide Perico1, Pierluigi Mauri1,2
1Institute of Biomedical Technologies-National Research Council ITB-CNR, Via Fratelli Cervi 93, 20054 Milan, Italy.
Abstract:
Radiotherapy resistance represents a critical aspect of cancer treatment, and molecular characterization is needed to explore the pathways and mechanisms involved. DNA repair, hypoxia, metabolic reprogramming, apoptosis, tumor microenvironment modulation, and activation of cancer stem cells are the primary mechanisms that regulate radioresistance, and understanding their complex interactions is essential for planning the correct therapeutic strategy. Proteomics has emerged as a key approach in precision medicine to study tumor heterogeneity and treatment response in cancer patients. The integration of mass spectrometry-based techniques with bioinformatics has enabled high-throughput, quantitative analyses to identify biomarkers, pathways, and new potential therapeutic targets. This review highlights recent advances in proteomic technologies and their application in identifying biomarkers predictive of radiosensitivity and radioresistance in different tumors, including head and neck, breast, lung, and prostate cancers. Sample variability, data interpretation, and the translation of findings into clinical practice remain challenging elements of proteomics. However, technological advancements support its application in a wide range of topics, allowing a comprehensive approach to radiobiology, which helps overcome radiation resistance. Ultimately, incorporating proteomics into the radiotherapy workflow offers significant potential for enhancing treatment efficacy, minimizing toxicity, and guiding precision oncology strategies.
Insights
Proteomics can identify biomarkers to predict cancer patient response to radiotherapy, helping overcome treatment resistance. This approach aids in developing precision oncology strategies for better treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Radiotherapy resistance is a major challenge in cancer treatment.
- Understanding the molecular mechanisms of radioresistance is crucial for effective therapy.
- Proteomics offers a powerful tool for studying tumor heterogeneity and treatment response.
Purpose of the Study:
- To review recent advances in proteomic technologies for identifying biomarkers of radiosensitivity and radioresistance.
- To highlight the application of proteomics in various cancer types, including head and neck, breast, lung, and prostate cancers.
- To discuss the potential of proteomics in overcoming radiation resistance and guiding precision oncology.
Main Methods:
- Mass spectrometry-based proteomics for high-throughput, quantitative analyses.
- Bioinformatic integration for biomarker and pathway identification.
- Review of current literature on proteomics applications in radiobiology.
Main Results:
- Proteomics can identify key mechanisms regulating radioresistance, such as DNA repair, hypoxia, and metabolic reprogramming.
- Proteomic approaches have identified potential biomarkers predictive of radiosensitivity and radioresistance across different tumor types.
- Technological advancements are enhancing the comprehensive analysis of radiobiology.
Conclusions:
- Proteomics is a key approach in precision medicine for understanding tumor heterogeneity and treatment response.
- Incorporating proteomics into radiotherapy workflows can enhance treatment efficacy and minimize toxicity.
- Further advancements in proteomics will aid in overcoming radiation resistance and guiding personalized cancer treatment strategies.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...